Omeros Corporation to Announce Fourth Quarter and Year-end Financial Results on March 1, 2022

Rhea-AI Summary

Omeros Corporation (NASDAQ: OMER) will announce its fourth quarter and year-end financial results for the period ended December 31, 2021, on March 1, 2022, after market close. Management will host a conference call at 4:30 p.m. ET to discuss these results and recent developments. This press release highlights the company's ongoing commitment to developing therapeutics for inflammatory and immunologic diseases, such as its lead product narsoplimab, currently pending FDA approval for treating specific conditions.

Positive

• Pending FDA approval for narsoplimab highlights potential revenue growth.
• Ongoing late-stage clinical trials for multiple conditions could lead to significant market opportunities.

Negative

• None.

SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (NASDAQ: OMER) today announced that the company will issue its fourth quarter and year-end financial results for the period ended December 31, 2021, on Tuesday, March 1, 2022, after the market closes. Omeros management will host a conference call and webcast that day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights.

Conference Call Details
To access the live conference call via phone, please dial (844) 831-4029 from the United States and Canada or (920) 663-6278 internationally. The participant passcode is 2686968. Please dial in approximately 10 minutes prior to the start of the call. A telephone replay will be available for one week following the call and may be accessed by dialing (855) 859-2056 from the United States and Canada or (404) 537-3406 internationally. The replay passcode is 2686968.

To access the live and subsequently archived webcast of the conference call, go to Omeros’ website at https://investor.omeros.com/upcoming-events.

About Omeros Corporation
Omeros is an innovative biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting inflammation, immunologic diseases (e.g., complement-mediated diseases) and cancers. Omeros’ lead MASP-2 inhibitor narsoplimab targets the lectin pathway of complement and is the subject of a biologics license application pending before FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Narsoplimab is also in multiple late-stage clinical development programs focused on other complement-mediated disorders, including IgA nephropathy, atypical hemolytic uremic syndrome and COVID-19. OMS906, Omeros’ inhibitor of MASP-3, the key activator of the alternative pathway of complement, is in a Phase 1 clinical trial. For more information about Omeros and its programs, visit www.omeros.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220224005486/en/

Jennifer Cook Williams

Cook Williams Communications, Inc.

Investor and Media Relations

IR@omeros.com

Source: Omeros Corporation

FAQ

When will Omeros report its financial results for Q4 2021?

Omeros will report its fourth quarter and year-end financial results on March 1, 2022, after market close.

What conference call details are available for Omeros' financial results?

The conference call will occur on March 1, 2022, at 4:30 p.m. ET. Dial in at (844) 831-4029 for US and Canada or (920) 663-6278 internationally.

What is the status of narsoplimab with respect to FDA approval?

Narsoplimab is currently under a biologics license application pending before the FDA for treating hematopoietic stem cell transplant-associated thrombotic microangiopathy.

What are the key areas of development for Omeros?

Omeros focuses on therapies for inflammation, immunologic diseases, and cancers, particularly related to complement-mediated disorders.